Carsten Holzmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1426498/publications.pdf

Version: 2024-02-01

53	2,216	361413	223800
papers	citations	20 h-index	46 g-index

53	53	53	3108
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Olfactory Bulb D2/D3 Receptor Availability after Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinsonâ€™s Disease. Toxins, 2022, 14, 94.	3.4	4
2	Differential Cellular Balance of Olfactory and Vomeronasal Epithelia in a Transgenic BACHD Rat Model of Huntingtonâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 7625.	4.1	0
3	Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1. International Journal of Molecular Sciences, 2021, 22, 2539.	4.1	7
4	Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinsonâ€™s Disease. Toxins, 2021, 13, 505.	3.4	9
5	Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids. In Vivo, 2020, 34, 1-9.	1.3	9
6	Repeated intrastriatal application of botulinum neurotoxin-A did not influence choline acetyltransferase-immunoreactive interneurons in hemiparkinsonian rat brain â€“ A histological, stereological and correlational analysis. Brain Research, 2020, 1742, 146877.	2.2	5
7	Interlinking potential therapy with botulinum neurotoxin-A and Parkinson's disease. , 2020, , 665-681.		1
8	Current Challenges in Understanding the Cellular and Molecular Mechanisms in Niemannâ€“Pick Disease Type C1. International Journal of Molecular Sciences, 2019, 20, 4392.	4.1	27
9	Botulinum Neurotoxin-A Injected Intrastriatally into Hemiparkinsonian Rats Improves the Initiation Time for Left and Right Forelimbs in Both Forehand and Backhand Directions. International Journal of Molecular Sciences, 2019, 20, 992.	4.1	7
10	High Speed Ventral Plane Videography as a Convenient Tool to Quantify Motor Deficits during Pre-Clinical Experimental Autoimmune Encephalomyelitis. Cells, 2019, 8, 1439.	4.1	19
11	Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior. Toxins, 2018, 10, 368.	3.4	11
12	Unilateral Botulinum Neurotoxin-A Injection into the Striatum of C57BL/6 Mice Leads to a Different Motor Behavior Compared with Rats. Toxins, 2018, 10, 295.	3.4	9
13	What are the differences in injury patterns of young and elderly traffic accident fatalities considering death on scene and death in hospital?. International Journal of Legal Medicine, 2017, 131, 1023-1037.	2.2	14
14	Intrastriatally injected botulinum neurotoxin-A differently effects cholinergic and dopaminergic fibers in C57BL/6 mice. Brain Research, 2017, 1676, 46-56.	2.2	12
15	Analysis of Injury and Mortality Patterns in Deceased Patients with Road Traffic Injuries: An Autopsy Study. World Journal of Surgery, 2017, 41, 3111-3119.	1.6	17
16	Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinsonâ€™s Disease Differently Affects Behavior. Frontiers in Behavioral Neuroscience, 2017, 11, 119.	2.0	16
17	Increased Regenerative Capacity of the Olfactory Epithelium in Niemannâ€“Pick Disease Type C1. International Journal of Molecular Sciences, 2017, 18, 777.	4.1	20
18	Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth. Oncotarget, 2017, 8, 34762-34772.	1.8	22

#	Article	IF	Citations
19	Case Report: A Low-grade Uterine Leiomyosarcoma Showing Multiple Genetic Aberrations Including a Bi-allelic Loss of the Retinoblastoma Gene Locus, as well as Germ-line Uniparental Disomy for Part of the Long Arm of Chromosome 22. Anticancer Research, 2017, 37, 2233-2237.	1.1	6
20	Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice. International Journal of Molecular Sciences, 2016, 17, 1866.	4.1	22
21	Malignant mesenchymal tumors of the uterus â€“ time to advocate a genetic classification. Expert Review of Anticancer Therapy, 2016, 16, 1155-1166.	2.4	8
22	Hyperhaploid uterine mesenchymal tumorsâ€”a novel genetic subgroup?. Cancer Genetics, 2016, 209, 278-281.	0.4	1
23	A rare coincidence of different types of driver mutations among uterine leiomyomas (UL). Molecular Cytogenetics, 2015, 8, 76.	0.9	14
24	Structural Connectivity Changes Underlying Altered Working Memory Networks in Mild Cognitive Impairment: A Threeâ€Way Image Fusion Analysis. Journal of Neuroimaging, 2015, 25, 634-642.	2.0	10
25	Genetic alterations in uterine fibroids â€“ a new direction for pharmacological intervention?. Expert Opinion on Therapeutic Targets, 2015, 19, 1485-1494.	3.4	14
26	Differential Redox Regulation of Ca2+ Signaling and Viability in Normal and Malignant Prostate Cells. Biophysical Journal, 2015, 109, 1410-1419.	0.5	36
27	Transient receptor potential melastatin 4 channel contributes to migration of androgen-insensitive prostate cancer cells. Oncotarget, 2015, 6, 41783-41793.	1.8	58
28	Patterns of Chromosomal Abnormalities that Can Improve Diagnosis of Uterine Smooth Muscle Tumors. Anticancer Research, 2015, 35, 6445-56.	1.1	10
29	Cytogenetically normal uterine leiomyomas without MED12-mutations â€“ a source to identify unknown mechanisms of the development of uterine smooth muscle tumors. Molecular Cytogenetics, 2014, 7, 88.	0.9	22
30	The Îµ4 genotype of apolipoprotein E and white matter integrity in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 401-404.	0.8	25
31	Comparative sensitivity analyses of quantitative polymerase chain reaction and flow cytometry in detecting cellular microchimerism in murine tissues. Journal of Immunological Methods, 2014, 406, 74-82.	1.4	9
32	Genome-wide acquired uniparental disomy as well as chromosomal gains and losses in an uterine epithelioid leiomyoma. Molecular Cytogenetics, 2014, 7, 19.	0.9	9
33	Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemannâ€“Pick Type C1 mice. Neuroscience, 2013, 252, 201-211.	2.3	43
34	Co-occurrence of multiple sclerosis and cancer in a BRCA1 positive family. European Journal of Medical Genetics, 2013, 56, 577-579.	1.3	7
35	Lifelong Caloric Restriction Increases Working Memory in Mice. PLoS ONE, 2013, 8, e68778.	2.5	80
36	Effects of intrastriatal botulinum neurotoxin A on the behavior of Wistar rats. Behavioural Brain Research, 2012, 234, 107-116.	2.2	31

#	Article	IF	Citations
37	A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiology of Disease, 2010, 37, 284-293.	4.4	51
38	Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Human Molecular Genetics, 2009, 18, 4282-4295.	2.9	97
39	Ageâ€dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. Proteomics - Clinical Applications, 2008, 2, 1638-1650.	1.6	17
40	Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease. Journal of Neuroscience, 2008, 28, 2471-2484.	3.6	164
41	Expression mapping of tetracycline-responsive prion protein promoter: Digital atlasing for generating cell-specific disease models. NeuroImage, 2006, 33, 449-462.	4.2	26
42	Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats. Neurobiology of Disease, 2006, 22, 538-547.	4.4	65
43	Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Human Molecular Genetics, 2006, 15, 3177-3194.	2.9	109
44	Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation. Journal of Neurochemistry, 2005, 94, 639-650.	3.9	53
45	Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation. Journal of Neurochemistry, 2005, 94, 1167-1167.	3.9	0
46	Polymorphisms of the Î±-synuclein promoter: expression analyses and association studies in Parkinson's disease. Journal of Neural Transmission, 2003, 110, 67-76.	2.8	53
47	14-3-3 proteins in the nervous system. Nature Reviews Neuroscience, 2003, 4, 752-762.	10.2	405
48	Transgenic rat model of Huntington's disease. Human Molecular Genetics, 2003, 12, 617-624.	2.9	329
49	Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Human Molecular Genetics, 2003, 12, 1223-1231.	2.9	124
50	14-3-3 protein is a component of Lewy bodies in Parkinsonâ€™s diseaseâ€”Mutation analysis and association studies of 14-3-3 eta. Molecular Brain Research, 2002, 108, 33-39.	2.3	53
51	Neurofilament L gene is not a genetic factor of sporadic and familial Parkinsonâ€™s disease. Brain Research, 2002, 951, 82-86.	2.2	16
52	Functional characterization of the human Huntingtonâ€™s disease gene promoter. Molecular Brain Research, 2001, 92, 85-97.	2.3	17
53	Isolation and characterization of the rat huntingtin promoter. Biochemical Journal, 1998, 336, 227-234.	3.7	23